FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

227 letters match. Newest first.

  1. ABR Laboratory LLC

    FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

    High risk
  2. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  3. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  4. Atlanta Supersource, Inc.

    Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.

    High risk
  5. Akron Formulations India Private Limited

    Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.

    High risk
  6. Guangzhou Four E’s Scientific Co., Ltd.

    FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.

    High risk
  7. Catwalk Cosmetic Laboratories Pty Ltd.

    FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.

    High risk
  8. Hangzhou Huiji Biotechnology Co., Ltd.

    FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.

    High risk
  9. Originitalia SRL

    FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.

    High risk
  10. Multaler et Cie SAS

    FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.

    High risk
  11. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk
  12. Omni Lens Pvt. Ltd.

    FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.

    High risk
  13. Outin Futures Corp.

    FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.

    High risk
  14. Makra Kozmetika D.O.O.

    FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

    High risk
  15. Clean Solutions LLC

    FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.

    High risk
  16. Avaria Health & Beauty Corp.

    FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.

    High risk
  17. Orean Personal Care Ltd.

    FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.

    High risk
  18. Media Networks Sydney Pty Limited

    Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.

    Low
  19. LS Promotions Inc.

    LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.

    High risk
  20. Nowrez & Ismail Shukri Company

    FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.

    High risk
  21. Yahon Enterprise Co., Ltd.

    FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

    High risk
  22. YangZhou SuXiang Medical Instrument Co., Ltd.

    FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.

    High risk
  23. Max Chemical Inc.

    FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.

    High risk
  24. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  25. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  26. Fancystage Unipessoal, LDA

    FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.

    High risk
  27. Cosmetic Solutions, LLC

    FDA warns Cosmetic Solutions over manufacturing failures and unapproved OTC drugs at Boca Raton plant.

    High risk
  28. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  29. Natuzen Co., Ltd.

    Natuzen Co., Ltd. failed drug manufacturing rules for OTC products including Atoren Hand Sanitizer, with no methanol testing, cleaning validation, or quality unit.

    High risk
  30. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  31. Cohere Beauty

    FDA cites Cohere Beauty for unvalidated OTC drug manufacturing and inadequate quality oversight at its Santa Fe Springs facility.

    Medium
  32. Global Cosmetics Company Limited

    FDA warns Global Cosmetics over manufacturing quality failures in OTC hand sanitizer, including no methanol testing of ethanol.

    High risk
  33. C&T Dream Co., Ltd.

    C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.

    High risk
  34. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  35. Jiangsu Meifan Biotechnology Co. Ltd.

    FDA cites Jiangsu Meifan Biotechnology for OTC drug manufacturing-rule failures and import alert.

    High risk
  36. Bodywell Natural Skin Care Inc.

    FDA warned Bodywell Natural Skin Care that its OTC hand sanitizer and Dermalere creams were adulterated due to CGMP failures and unapproved drug claims.

    High risk
  37. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  38. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  39. Thai Nakorn Patana Co., Ltd.

    FDA warns Thai Nakorn Patana over manufacturing quality violations, including missing identity and strength testing before release of OTC drugs.

    High risk
  40. Delsam Pharma LLC

    Delsam Pharma distributed non-sterile, contaminated artificial tears and eye ointment made by its contract manufacturer, FDA found.

    High risk
  41. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  42. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  43. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  44. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  45. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  46. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  47. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  48. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  49. Cerci Kozmetik Ve Otel Ekipmanlari Pazarlama Ic Ve Dis Ticaret Limited Sirketi

    FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.

    High risk
  50. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk